Commons Sense

House of Commons · Westminster Hall

Motor Neurone Disease Research: Government Funding

13 December 2022 · 3 other contributors · 3,065 words

Opened by Karl Turner Ind Kingston upon Hull East

Responding minister: Not recorded

NHS

Summarised by AI from the official record, so it can contain mistakes.

At a glance

Karl Turner raised concerns about motor neurone disease research: government funding in Westminster Hall. Response awaited from government.

Key points

  • Motor Neurone Disease is a fatal condition with six deaths daily in the UK.
  • The MND Association reports one-third of patients die within one year of diagnosis.
  • The Government pledged to invest 50 million but has not fulfilled this promise for over a year.

Key requests to Government

The lead MP asks the Minister to arrange a meeting between MND campaigners and the Secretaries of State for Health and Social Care and BEIS to provide clarity on when and how the promised funding will be made available.

How the debate unfolded

MPs spoke in turn to share their views and ask questions. Here's what each person said.

Opened the debate

Karl Turner Ind Kingston upon Hull East

MND is a devastating and untimely disease, with six people dying of it daily in the UK. The MND Association estimates that a third of those diagnosed die within one year. Following meetings with campaigners and the Business Secretary, the Government pledged to invest £50 million but failed to deliver on this promise for over 12 months.

Other contributors (3)
  • He thanked the Government for listening and making important announcements regarding MND research funding. Mr Lewer expressed his gratitude towards these actions and looked forward to further collaboration with the Minister.

  • Chris Evans Lab Co-op Caerphilly

    Mr Evans raised concerns about a higher incidence of MND among sportsmen and urged GPs to test for MND early in patients' journeys, as late diagnosis can be detrimental.

  • Jim Shannon DUP Strangford

    The hon. Member highlighted the lack of adequate care and provision for MND in Northern Ireland, stressing the importance of improving access to clinical trials across the UK.

Get updates like this by email
▸ Assessment & feedback
Summary accuracy